Srisukipharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 7.88 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 3048.52%
- Profit Growth 281.22%
- Ebitda 268.79%
- Net Worth 193.73%
- Total Assets 214.19%
About Srisukipharma
Srisukipharma Private Limited (SPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 October 2018 (Six years and four months 2 days old ). Its registered office is in Vellore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 7.88 M, as per Ministry of Corporate Affairs (MCA) records.
Balaji Nandagopal, Shanthi Balaji, and Ho Linfo serve as directors at the Company.
Company Details
-
Location
Vellore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999TN2018PTC125182
-
Company No.
125182
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Oct 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Srisukipharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Balaji Nandagopal
|
Director | 09-Oct-2018 | Current |
|
Shanthi Balaji
|
Director | 09-Oct-2018 | Current |
Ho Linfo
|
Director | 31-Jul-2019 | Current |
Financial Performance of Srisukipharma.
Srisukipharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 3048.52% increase. The company also saw a substantial improvement in profitability, with a 281.22% increase in profit. The company's net worth Soared by an impressive increase of 193.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srisukipharma?
In 2021, Srisukipharma had a promoter holding of 4.69% and a public holding of 95.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sri Vidhya Pharma Private LimitedBalaji Nandagopal is a mutual person
-
Srisuki Promoters And Developers Private Limited
Balaji Nandagopal and Ho Linfo are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Srisukipharma?
Unlock and access historical data on people associated with Srisukipharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srisukipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srisukipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.